Postinflammatory hyperpigmentationhttps://en.wikipedia.org/wiki/Hyperpigmentation
Postinflammatory hyperpigmentation se yon maladi po ki karakterize pa ogmante pigman nan po a apre enflamasyon po a. Postinflammatory hyperpigmentation ka koze pa ekspoze solèy pwolonje, enflamasyon, oswa lòt blesi sou po, tankou sa ki gen rapò ak akne. Moun ki gen ton po pi fonse yo anjeneral gen plis tandans fè ipèpigmantasyon ak ekspoze solèy depase.

☆ Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
      References Postinflammatory Hyperpigmentation 32644576 
      NIH
      Postinflammatory hyperpigmentation (PIH) se yon pwoblèm po souvan ki rive apre enflamasyon po oswa blesi. Li gen tandans dire yon tan long epi li vin pi mal nan moun ki gen ton po pi fonse (Fitzpatrick skin types III–VI) . Malgre ke li souvan vin pi bon poukont li, sa ka pran yon ti tan, kidonk tretman souvan nesesè pou yon tan long. Konbine diferan tretman travay pi byen.
      Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
       Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color 20725554 
      NIH
      Postinflammatory hyperpigmentation se yon konsekans komen nan enflamasyon po. Li gen tandans afekte moun ki gen po fonse pi grav epi souvan. Etid yo montre ke pwoblèm tankou postinflammatory hyperpigmentation se yo ki pami rezon prensipal poukisa moun ki gen koulè po pi fonse chèche swen dèrmatolojik. Tretman bonè enpòtan anpil pou rezoud postinflammatory hyperpigmentation epi anjeneral kòmanse ak jere kondisyon enflamatwa inisyal la. Premye liy tretman an anjeneral enplike nan itilize ajan aktualite ki aleje po a ansanm ak krèm pwotèj kont solèy pou pwoteksyon. Ajan sa yo, tankou hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , ka efektivman diminye pigmantasyon twòp. Anplis de sa, retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy yo itilize tou kòm ajan depigmantasyon, ak nouvo tretman k ap parèt. Pandan ke tretman aktualite yo anjeneral efikas pou hyperpigmentation nivo sifas, pwosedi (laser, chemical peel) ka nesesè pou ka fè tèt di. Li enpòtan pou w pran prekosyon ak tretman sa yo pou evite iritasyon ak vin pi grav nan postinflammatory hyperpigmentation.
      Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.